10-Q: Alzamend Neuro Reports Q1 2024 Results, Focuses on Clinical Trials and Funding

Alzamend Neuro reported a net loss of $974,411 for the quarter ended July 31, 2024, while advancing clinical trials and securing funding through preferred stock sales.

Summary

• Alzamend Neuro, a clinical-stage biopharmaceutical company, reported a net loss of $974,411 for the three months ended July 31, 2024, compared to a net loss of $3,527,766 for the same period in 2023.
• The company's operating expenses decreased significantly, with research and development expenses dropping from $2,366,137 to $206,571 year-over-year.
• General and administrative expenses also decreased from $1,159,794 to $755,834 over the same period.
• The company's cash position improved to $1,193,950 as of July 31, 2024, up from $376,048 at the end of April 2024, primarily due to financing activities.
• Alzamend is focused on advancing its two product candidates, AL001 and ALZN002, through clinical trials for the treatment of Alzheimer's, bipolar disorder, major depressive disorder, and PTSD.
• The company has raised capital through the sale of Series A and Series B Convertible Preferred Stock, including $1.0 million on May 10, 2024, and $1.5 million on June 25, 2024.
• The company has a working capital deficiency of $1.5 million and an accumulated deficit of $55.0 million as of July 31, 2024.
• The company believes its current cash on hand is not sufficient to fund its planned operations through one year after the date the condensed financial statements are issued.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has made progress in reducing losses and securing funding, it faces significant challenges, including a going concern risk, material weaknesses in internal controls, and a delay in clinical trials. The overall sentiment is cautiously negative.

Positives

• The company significantly reduced its net loss and operating expenses compared to the same period last year.
• The company's cash position improved due to successful financing activities.
• The company is actively progressing its clinical trials for AL001 and ALZN002.
• The company secured additional funding through the sale of preferred stock and warrants.
• The company has partnered with Massachusetts General Hospital to serve as the CRO for clinical trials.

Negatives

• The company continues to operate at a loss and has a significant accumulated deficit.
• The company has a working capital deficiency of $1.5 million.
• The company's current cash on hand is not sufficient to fund its planned operations through one year after the date the condensed financial statements are issued.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company terminated its contract with its previous CRO, Biorasi, LLC, and is seeking a replacement.

Risks

• The company's ability to continue as a going concern is in doubt due to its recurring losses and insufficient cash flow.
• The company needs to raise additional capital to fund its operations and clinical trials.
• The company's clinical trials may not be successful, and its product candidates may not receive regulatory approval.
• The company faces competition from other biopharmaceutical companies.
• The company has identified material weaknesses in its internal control over financial reporting, which could lead to misstatements in its financial statements.

Future Outlook

The company expects to continue to incur losses for the foreseeable future and needs to raise additional capital until it is able to generate revenues from operations sufficient to fund its development and commercial operations. Management believes that the company's cash and cash equivalents at July 31, 2024, together with the anticipated receipt of funds from the sale of its Series A and Series B Convertible Preferred Stock, will be sufficient to meet the company's anticipated cash requirements during the twelve-month period subsequent to the issuance of the financial statements.

Management Comments

• Management believes its current cash on hand is not sufficient to fund its planned operations through one year after the date the condensed financial statements are issued.
• Management believes that the company's cash and cash equivalents at July 31, 2024, together with the anticipated receipt of funds from the sale of its Series A and Series B Convertible Preferred Stock, will be sufficient to meet the company's anticipated cash requirements during the twelve-month period subsequent to the issuance of the financial statements.

Industry Context

Alzamend is operating in the competitive biopharmaceutical industry, focusing on treatments for neurological and psychiatric disorders. The company's approach to Alzheimer's treatment through immunotherapy and a novel lithium formulation is aimed at addressing unmet needs in the market. The company is competing with other companies developing treatments for similar conditions.

Comparison to Industry Standards

• Alzamend's significant reduction in R&D spending this quarter is notable, as many biotech companies at this stage often have high R&D costs. For example, companies like Cassava Sciences (SAVA) and Annovis Bio (ANVS), which are also developing Alzheimer's treatments, have reported higher R&D expenses in their recent quarterly reports.
• The company's cash position of $1.2 million is relatively low compared to other clinical-stage biotechs. For instance, companies like Amylyx Pharmaceuticals (AMLX) and Biogen (BIIB), which have approved products, have significantly higher cash reserves.
• The company's reliance on preferred stock sales for funding is common among early-stage biotechs, but it also indicates a higher risk profile compared to companies with more diversified funding sources. Companies like Sage Therapeutics (SAGE) and Karuna Therapeutics (KRTX) have secured funding through partnerships and collaborations, which can be less dilutive to existing shareholders.
• The company's accumulated deficit of $55 million is typical for a company at this stage of development, but it highlights the need for successful clinical trials and commercialization to achieve profitability. Companies like Prothena (PRTA) and AC Immune (ACIU), which are also developing Alzheimer's treatments, have similar accumulated deficits.
• The company's focus on AL001 and ALZN002 is similar to other companies developing novel treatments for Alzheimer's, but the company's approach of using a cocrystal of lithium and a cell-based therapeutic vaccine is unique. Companies like Eli Lilly (LLY) and Eisai (ESALY) are developing monoclonal antibodies, which are a different approach to treating Alzheimer's.

Related Party Transactions

• The company agreed to pay Ault Lending an origination fee of five percent (5%) of the total gross proceeds we receive from Orchid upon each purchase of Series A Convertible Preferred Stock. During the three months ended July 31, 2024, origination fees due to Ault Lending were $125,000.

Stakeholder Impact

• Shareholders face the risk of dilution due to the issuance of preferred stock and warrants.
• Employees may be affected by the company's financial instability and potential delays in clinical trials.
• Customers (potential patients) may experience delays in the development of new treatments.
• Suppliers and creditors may face increased risk due to the company's financial challenges.

Next Steps

• The company intends to initiate clinical trials in 2025 at the identified maximum tolerated dose (MTD) to determine relative increased lithium levels in the brain compared to a marketed lithium salt for Alzheimers, BD, MDD and PTSD.
• The company is pursuing the engagement of a replacement CRO.
• The company will continue to implement measures to remediate material weaknesses in its internal control over financial reporting.

Key Dates

Keywords

Alzamend Neuro, AL001, ALZN002, clinical trials, biopharmaceutical, Alzheimer's disease, bipolar disorder, major depressive disorder, PTSD, preferred stock, warrants, financial results, research and development, net loss, going concern